Real-World Outcomes in the Evolving Second-Line Systemic Therapy Landscape in Hepatocellular Carcinoma: A Single-Institution Experience.

Authors

Mark F deBettencourt, Kayeromi Gomez, Nina Undevia Yedavalli

Published in

American journal of clinical oncology. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Historically, few treatments existed for hepatocellular carcinoma (HCC) until sorafenib's approval in 2007. Meaningful treatment advances included approval of atezolizumab plus bevacizumab in 2020 and tremelimumab plus durvalumab in 2022. However, optimal second-line systemic therapy and outcomes after current first-line therapies are unclear.
Patients treated with systemic therapy for HCC between 2018 and 2025 were retrospectively reviewed. Demographics, clinical characteristics, treatment history, and survival outcomes were collected. Survival was analyzed using Kaplan-Meier methods. Univariable and multivariable analyses were conducted.
In total, 143 patients were reviewed (median age 67.4; 72.0% male). First-line systemic therapy included sorafenib (28.0%), nivolumab (21.0%), lenvatinib (18.9%), atezolizumab/bevacizumab (16.1%), and tremelimumab/durvalumab (8.4%). Fifty-two patients (36.4%) received second-line therapy: immunotherapy (48.1%), TKI (40.4%), and ramucirumab (11.5%). AFP ≥400 was present in 48.1% of second-line patients. Leading barriers to second-line treatment were patient choice (40.7%) and poor performance status (38.5%). Median overall survival after second-line therapy was 8.5, 9.1, and 9.3 months for TKI, immunotherapy, and ramucirumab, respectively (P=0.903). Median progression-free survival was 3.1, 3.9, and 3.7 months (P=0.598).
One third of patients received second-line therapy, with patient choice and declining performance status as leading barriers. Ramucirumab's underutilization, comparable efficacy, and favorable toxicity profile make it worthy of increased consideration for second-line systemic therapy. Prospective studies are needed to elucidate factors influencing optimal second-line therapy in HCC.

PMID:
42832639
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.